Efficacy and safety analysis according to histology for s-1 in combination with carboplatin as first-line chemotherapy in patients with advanced non-small-cell lung cancer: Updated results of the west japan oncology group lets study

H. Yoshioka, I. Okamoto, S. Morita, M. Ando, K. Takeda, T. Seto, N. Yamamoto, H. Saka, S. Atagi, T. Hirashima, S. Kudoh, M. Satouchi, N. Ikeda, Y. Iwamoto, T. Sawa, Y. Nakanishi, K. Nakagawa

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Background: A phase III study (Lung Cancer Evaluation of TS-1) previously demonstrated noninferiority in terms of overall survival (OS) at interim analysis for carboplatin-S-1 compared with carboplatin-paclitaxel for first-line treatment of advanced non-small-cell lung cancer (NSCLC). Patients and methods: A total of 564 patients were randomly assigned to receive either carboplatin on day 1 plus oral S-1 on days 1-14 or carboplatin-paclitaxel on day 1 every 21 days. Updated results and post hoc subgroup analysis according to tumor histology are presented. Results: The updated analysis revealed a median OS of 15.2 months in the carboplatin-S-1 arm and 13.1 months in the carboplatin-paclitaxel arm, with a hazard ratio (HR) of 0.956 [95% confidence interval (CI) 0.793-1.151], consistent with the previous primary analysis. Median OS was 14.0 months in the carboplatin-S-1 arm and 10.6 months in the carboplatin-paclitaxel arm (HR 0.713; 95% CI 0.476-1.068) for patients with squamous cell carcinoma (SCC), with corresponding values of 15.5 and 13.9 months (HR 1.060; 95% CI 0.859-1.308) for those with non-SCC. Conclusions: These results establish the efficacy and safety of carboplatin-S-1 in patients with advanced NSCLC regardless of tumor histology.

Original languageEnglish
Article numbermds629
Pages (from-to)1326-1331
Number of pages6
JournalAnnals of Oncology
Volume24
Issue number5
DOIs
Publication statusPublished - May 2013

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Efficacy and safety analysis according to histology for s-1 in combination with carboplatin as first-line chemotherapy in patients with advanced non-small-cell lung cancer: Updated results of the west japan oncology group lets study'. Together they form a unique fingerprint.

  • Cite this

    Yoshioka, H., Okamoto, I., Morita, S., Ando, M., Takeda, K., Seto, T., Yamamoto, N., Saka, H., Atagi, S., Hirashima, T., Kudoh, S., Satouchi, M., Ikeda, N., Iwamoto, Y., Sawa, T., Nakanishi, Y., & Nakagawa, K. (2013). Efficacy and safety analysis according to histology for s-1 in combination with carboplatin as first-line chemotherapy in patients with advanced non-small-cell lung cancer: Updated results of the west japan oncology group lets study. Annals of Oncology, 24(5), 1326-1331. [mds629]. https://doi.org/10.1093/annonc/mds629